General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-10-29 | 2024-09 | 1.92 | N/A | N/A | N/A |
2024-07-18 | 2024-06 | 1.87 | 1.97 | 0.1 | 5.35% |
2024-04-23 | 2024-03 | 1.73 | 1.8 | 0.07 | 4.05% |
2024-01-31 | 2023-12 | 1.64 | 1.53 | -0.11 | -6.71% |
2023-10-24 | 2023-09 | 1.7 | 1.74 | 0.04 | 2.35% |
2023-07-18 | 2023-06 | 1.68 | 1.83 | 0.15 | 8.93% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
2022-05-08 | Wolfe Research | Downgrade | Outperform | Peer Perform |
2021-12-05 | Exane BNP Paribas | Downgrade | Outperform | Neutral |
2021-12-02 | Bryan Garnier | Downgrade | Buy | Neutral |
2021-09-19 | Deutsche Bank | Downgrade | Hold | Sell |
2021-03-09 | Argus Research | Downgrade | Buy | Hold |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Dodge & Cox Inc | 16.41M | 1.66B | 0.72% |
2023-06-29 | Primecap Management Company | 15.01M | 1.51B | 0.66% |
2023-06-29 | Morgan Stanley | 7.27M | 733.15M | 0.32% |
2023-06-29 | Loomis Sayles & Company, LP | 6.32M | 637.25M | 0.28% |
2023-06-29 | Dimensional Fund Advisors LP | 6.26M | 631.43M | 0.27% |
2023-06-29 | Franklin Resources, Inc. | 6.18M | 623.98M | 0.27% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Dodge & Cox Stock Fund | 11.82M | 1.19B | 0.52% |
2023-06-29 | Vanguard/Primecap Fund | 9.01M | 908.75M | 0.40% |
2023-06-29 | Franklin Mutual Series Fund-Mutual Global Discovery Fund | 2.34M | 235.69M | 0.10% |
2023-06-29 | Vanguard Horizon Fund-Capital Opportunity Fund | 2.23M | 225.13M | 0.10% |
2023-07-30 | Hartford Dividend & Growth Fund | 2.04M | 214.49M | 0.09% |
2023-07-30 | Principal Equity Income Fd | 1.91M | 200.84M | 0.08% |
Dividend | Date |
---|---|
3.77721 | 2024-09-24 |
3.7772 | 2024-03-07 |
3.46936 | 2023-03-09 |
3.357 | 2022-03-08 |
3.378 | 2021-03-04 |
3.042 | 2020-03-03 |
Split | Date |
---|---|
1.11607 : 1 | 2019-04-09 |
2 : 1 | 2000-05-11 |
manufacturer of xolair, which can reduce the risk of extreme allergic reaction in children. Amazing
$PTC Therapeutics(PTCT.US)$ Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
I can proudly say my broker is one of the best manager Karen J Adams in Crypto market, I invested $7,000 and I made $90,810 after few days of trade. Message her to be your guidance about trading she is on What'sApp +𝟏𝟖𝟏𝟐𝟐𝟕𝟎𝟔𝟖𝟎𝟕
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, here is the CORE issue with
Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. That the efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!